Second-line treatment in renal cell carcinoma: clinical experience and decision making.
Valentina GuadalupiGiacomo CartenìRoberto IacovelliCamillo PortaGiovanni PappagalloRiccardo RicottaGiuseppe ProcopioPublished in: Therapeutic advances in urology (2021)
The result of this paper was the definition of an algorithm intended to suggest a preferential therapeutic pathway considering both the outputs of the Nominal Group Technique (NGT) process and the actual clinical practice and the experience of selected panelists. During the NGT process and the discussion phase, panelists defined the most important parameters to be included in the algorithm that are important for the treatment definition. Cabozantinib and nivolumab are identified as the most reasonable therapeutic options for patients progressing after first-line treatment and are the medication options included in the algorithm for therapy selection.